Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

PURPOSE: We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma. PATIENTS AND METHODS: In this open label phase II study (NCT00253630), patients with relapsed/refra...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kirschbaum, Mark, Frankel, Paul, Popplewell, Leslie, Zain, Jasmine, Delioukina, Maria, Pullarkat, Vinod, Matsuoka, Deron, Pulone, Bernadette, Rotter, Arnold J., Espinoza-Delgado, Igor, Nademanee, Auayporn, Forman, Stephen J., Gandara, David, Newman, Edward
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3083875/
https://ncbi.nlm.nih.gov/pubmed/21300924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.1398
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares